Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

186 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
CT screening for lung cancer: five-year prospective experience.
Swensen SJ, Jett JR, Hartman TE, Midthun DE, Mandrekar SJ, Hillman SL, Sykes AM, Aughenbaugh GL, Bungum AO, Allen KL. Swensen SJ, et al. Among authors: mandrekar sj. Radiology. 2005 Apr;235(1):259-65. doi: 10.1148/radiol.2351041662. Epub 2005 Feb 4. Radiology. 2005. PMID: 15695622
Randomized phase II trial of three schedules of pemetrexed and gemcitabine as front-line therapy for advanced non-small-cell lung cancer.
Ma CX, Nair S, Thomas S, Mandrekar SJ, Nikcevich DA, Rowland KM, Fitch TR, Windschitl HE, Hillman SL, Schild SE, Jett JR, Obasaju C, Adjei AA; North Central Cancer Treatment Group; Mayo Clinic; Eli Lilly & Company. Ma CX, et al. Among authors: mandrekar sj. J Clin Oncol. 2005 Sep 1;23(25):5929-37. doi: 10.1200/JCO.2005.13.953. J Clin Oncol. 2005. PMID: 16135464 Clinical Trial.
A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade), in combination with paclitaxel and carboplatin in patients with advanced malignancies.
Ma C, Mandrekar SJ, Alberts SR, Croghan GA, Jatoi A, Reid JM, Hanson LJ, Bruzek L, Tan AD, Pitot HC, Erlichman C, Wright JJ, Adjei AA. Ma C, et al. Among authors: mandrekar sj. Cancer Chemother Pharmacol. 2007 Feb;59(2):207-15. doi: 10.1007/s00280-006-0259-9. Epub 2006 Jun 9. Cancer Chemother Pharmacol. 2007. PMID: 16763792 Clinical Trial.
The value of combined-modality therapy in elderly patients with stage III nonsmall cell lung cancer.
Schild SE, Mandrekar SJ, Jatoi A, McGinnis WL, Stella PJ, Deming RL, Jett JR, Garces YI, Allen KL, Adjei AA; North Central Cancer Treatment GroupThis study was conducted as a collaborative trial of the North Central Cancer Treatment Group and the Mayo Clinic. Schild SE, et al. Among authors: mandrekar sj. Cancer. 2007 Jul 15;110(2):363-8. doi: 10.1002/cncr.22780. Cancer. 2007. PMID: 17542000 Free article. Clinical Trial.
Phase III randomized, double-blind study of maintenance CAI or placebo in patients with advanced non-small cell lung cancer (NSCLC) after completion of initial therapy (NCCTG 97-24-51).
Johnson EA, Marks RS, Mandrekar SJ, Hillman SL, Hauge MD, Bauman MD, Wos EJ, Moore DF, Kugler JW, Windschitl HE, Graham DL, Bernath AM Jr, Fitch TR, Soori GS, Jett JR, Adjei AA, Perez EA. Johnson EA, et al. Among authors: mandrekar sj. Lung Cancer. 2008 May;60(2):200-7. doi: 10.1016/j.lungcan.2007.10.003. Epub 2007 Nov 28. Lung Cancer. 2008. PMID: 18045731 Clinical Trial.
Endpoints in phase II trials for advanced non-small cell lung cancer.
Mandrekar SJ, Qi Y, Hillman SL, Allen Ziegler KL, Reuter NF, Rowland KM Jr, Kuross SA, Marks RS, Schild SE, Adjei AA. Mandrekar SJ, et al. J Thorac Oncol. 2010 Jan;5(1):3-9. doi: 10.1097/JTO.0b013e3181c0a313. J Thorac Oncol. 2010. PMID: 19884856 Free PMC article.
186 results